SCLX Stock Overview Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Scilex Holding Company Competitors Price History & Performance
Summary of share price highs, lows and changes for Scilex Holding Historical stock prices Current Share Price US$0.45 52 Week High US$2.63 52 Week Low US$0.43 Beta 0.97 1 Month Change -20.74% 3 Month Change -55.25% 1 Year Change -68.04% 3 Year Change -95.54% 5 Year Change n/a Change since IPO -95.46%
Recent News & Updates Scilex Holding Company has completed a Follow-on Equity Offering. Dec 14
Scilex Holding Company has filed a Follow-on Equity Offering. Dec 13
Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $16.966083 million. Dec 12
Scilex Bio Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to Be Added in 2025 Dec 11
Scilex Holding Announces Receipt of Notice from Nasdaq Nov 22 Scilex Holding Company announced delayed 10-Q filing Nov 15
See more updates Scilex Holding Company has completed a Follow-on Equity Offering. Dec 14
Scilex Holding Company has filed a Follow-on Equity Offering. Dec 13
Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $16.966083 million. Dec 12
Scilex Bio Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to Be Added in 2025 Dec 11
Scilex Holding Announces Receipt of Notice from Nasdaq Nov 22 Scilex Holding Company announced delayed 10-Q filing Nov 15
New minor risk - Shareholder dilution Nov 14 Scilex Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Nov 08
Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded Oct 24
Price target increased by 43% to US$7.63 Oct 16 Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $50 million. Oct 10
Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Quarter Ended September 30, 2024 Scilex Holding Company has filed a Follow-on Equity Offering. Oct 07
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label Aug 29
Consensus EPS estimates fall by 62%, revenue upgraded Aug 20
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 15
Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024 Aug 01
Scilex Holding Company Appoints Annu Navani as Board of Directors Jul 24
Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa™) in Lumbosacral Radicular Pain (Sciatica) Jun 15
Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically Jun 14
Consensus revenue estimates fall by 19% Jun 13
Scilex Holding Company Announces FDA Approval of Commercial Manufacturing of Gloperba Jun 08
President recently bought US$122k worth of stock May 19
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 15 Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $15 million.
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks Apr 24 Scilex Holding Company has filed a Follow-on Equity Offering. Apr 24
New minor risk - Market cap size Apr 19
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed Mar 21 Scilex Holding Company and Scilex Pharmaceuticals, Inc. Announces Settlement Agreement with Takeda Pharmaceuticals Company Ltd and Takeda Pharmaceuticals U.S.A., Inc
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 13
Scilex Holding Company, Annual General Meeting, Apr 05, 2024 Mar 13 Scilex Holding Company has filed a Follow-on Equity Offering. Mar 01
Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues Feb 28
Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023 Jan 02
Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada Dec 27
Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million. Dec 24 Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million. Dec 23
Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX) Dec 21
High number of new and inexperienced directors Dec 21
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing Dec 19
Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List (PDL) in Two New States: One Midwestern and One Southern State Dec 08
Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List (Pdl) of the State of the State of Tennessee Dec 04
Scilex Holding Company Announces Successful Fda Audit of Enhanced Ztlido®? Manufacturing Facility in Japan Nov 30
Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba Nov 29
Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba Nov 28
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs in Treating Acute Migraine Targeted by ELYXYB Nov 23
Scilex Holding Company Announces Production Increase, Product Availability Nov 22
Scilex Holding Company Announces Positive Type C Meeting with the Fda and Reaches Agreement on Path Forward to File an Nda for Sp-102 in Lumbosacral Radicular Pain (Sciatica) Nov 04
Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders Nov 03
Scilex Holding Company Announces Management Changes Sep 24 Scilex Holding Company Announces Management Changes
Scilex Holding Company Announces the Completion of its SP-103 Phase 2 Sep 15
Scilex Holding Company Presents Oral and Poster Presentations on ZTlido (lidocaine Topical System) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV Sep 13 Shareholder Returns SCLX US Pharmaceuticals US Market 7D -11.8% -1.6% -2.4% 1Y -68.0% 7.8% 23.3%
See full shareholder returns
Return vs Market: SCLX underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is SCLX's price volatile compared to industry and market? SCLX volatility SCLX Average Weekly Movement 15.7% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SCLX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SCLX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia.
Show more Scilex Holding Company Fundamentals Summary How do Scilex Holding's earnings and revenue compare to its market cap? SCLX fundamental statistics Market cap US$58.00m Earnings (TTM ) -US$171.53m Revenue (TTM ) US$50.83m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SCLX income statement (TTM ) Revenue US$50.83m Cost of Revenue US$16.14m Gross Profit US$34.69m Other Expenses US$206.22m Earnings -US$171.53m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.30 Gross Margin 68.24% Net Profit Margin -337.44% Debt/Equity Ratio -48.6%
How did SCLX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 02:13 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Scilex Holding Company is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Mayank Mamtani B. Riley Securities, Inc. Raghuram Selvaraju H.C. Wainwright & Co.
Show 1 more analysts 
